Other · developed by MapLight Therapeutics
ML-007C-MA is an investigational agent studied in psychosis associated with Alzheimer's disease and in schizophrenia.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06887192 | Phase 2 | Psychosis Associated With Alzheimer's Disease | Recruiting | MPLT |
| NCT07038876 | Phase 2 | Schizophrenia | Completed | MPLT |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Psychosis Associated With Alzheimer's DiseaseSchizophrenia
Updated Oct 25, 2026. Something wrong or missing? Report it on the MPLT page.
See MPLT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
MPLT catalysts and pipeline →